DURECT Corp Files 8-K on Financials
| Field | Detail |
|---|---|
| Company | Durect Corp |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
DURECT Corp dropped an 8-K on Aug 12th - check their financials!
AI Summary
DURECT Corporation filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 10240 Bubb Road, Cupertino, CA 95014. DURECT CORP is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides an update on DURECT Corporation's financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any immediate, significant risks.
Key Players & Entities
- DURECT CORP (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 943297098 (ein) — IRS Employer Identification No.
- 10240 Bubb Road, Cupertino, CA 95014 (address) — Principal executive offices
- 4087771417 (phone_number) — Registrant's telephone number
- August 12, 2025 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on August 12, 2025.
What is DURECT Corporation's principal executive office address?
The principal executive offices are located at 10240 Bubb Road, Cupertino, CA 95014.
In which state is DURECT Corporation incorporated?
DURECT Corporation is incorporated in Delaware.
What is the SIC code for DURECT Corporation?
The Standard Industrial Classification (SIC) code for DURECT Corporation is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-08-12 16:30:31
Key Financial Figures
- $0.0001 — ange on Which Registered Common Stock $0.0001 par value per share DRRX The NASDAQ
Filing Documents
- drrx-20250812.htm (8-K) — 50KB
- drrx-ex99_1.htm (EX-99.1) — 321KB
- 0000950170-25-107379.txt ( ) — 492KB
- drrx-20250812.xsd (EX-101.SCH) — 29KB
- drrx-20250812_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 12, 2025, DURECT Corporation, a Delaware corporation ("DURECT"), announced its second quarter ended June 30, 2025 financial results. This Current Report is filed to disclose nonpublic information required to be disclosed by Regulation FD. A copy of DURECT's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing .
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits ( d) Exhibits 99.1 Press Release of DURECT Corporation dated August 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DURECT Corporation Date: August 12, 2025 By: /s/ James E. Brown James E. Brown Chief Executive Officer 3